Raising HDL with Toremifine?

[Shelby]

A lot of guys take nolvadex to raise HDL.. but it looks like Toremifine might be a better choice.

Anyone have experience / input?

**broken link removed**

 

[stankyleg]

I dont know about how it effects hdl, but makes my boys nice and full

 

[dragonfire101]

Effect of toremifene in lowering total cholesterol, LDL, and triglycerides and raisin

Effect of toremifene in lowering total cholesterol, LDL, and triglycerides and raising HDL in prostate cancer patients on androgen deprivation therapy.


Sub-category:
Prostate Cancer

Category:
Genitourinary Cancer

Meeting:
2007 ASCO Annual Meeting

Session Type and Session Title:
General Poster Session, Genitourinary Cancer

Abstract No:
5124

Citation:
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 5124

Author(s):
M. Smith, F. Chu, J. Forrest, S. B. Malkowicz, D. Price, P. Sieber, K. G. Barnette, D. Rodriguez, M. S. Steiner

Abstract:

Introduction: Androgen deprivation therapy (ADT) is the standard treatment for men with advanced prostate cancer. ADT has been shown to detrimentally affect lipids (average 9% increase in total cholesterol and 26% increase in triglycerides) and is associated with increased risk of coronary heart disease and myocardial infarction. Toremifene, a selective estrogen receptor modulator (SERM), improves bone mineral density and lipid profiles in women. An ongoing phase III trial will assess the safety and efficacy of toremifene in treating multiple side effects of ADT including osteoporosis, hot flashes, gynecomastia and lipid profiles. Given the emerging recognition of increased cardiovascular risk during ADT, an interim analysis was conducted to assess the effects of toremifene on lipid profiles in the ongoing phase III study. Methods: 1,392 men = 50 years old with histologically documented prostate cancer and receiving ADT were randomized to toremifene (80 mg/day) or placebo. An interim analysis evaluated changes in lipids from baseline to month 12 in the first 197 subjects to complete one-year follow up. The outcomes measured in this interim analysis were total cholesterol, LDL cholesterol, triglycerides, total cholesterol/HDL ratio, and HDL cholesterol. Results: Compared to treatment with placebo, toremifene decreased total cholesterol (7.1%; p=0.001 for between group comparison), LDL cholesterol (9.0%; p=0.003), and triglycerides (20.1%; p=0.009) levels, and the total cholesterol/HDL ratio (11.7%; p<0.001). Toremifene also significantly increased HDL levels (5.4%; p=0.018) compared to placebo. The effects of toremifene were observed in both statin users and nonusers. Conclusions: Toremifene decreases total cholesterol, LDL cholesterol, and triglycerides and increases HDL cholesterol in men receiving ADT for advanced prostate cancer compared to placebo. Conclusions regarding the clinical significance of these observations will be based on the full cohort of patients at the conclusion of the trial.

 

[mikevegas]

I've used Torem with great success for PCT. Don't know how it effected my HDL, but put test count into orbit with no physical sides that I noticed.

 

[EDED]

postmenopause and intentional andropause (ADT)

**broken link removed**

wonder how we gear users who are APT (androgen plenty therapy) lol would be like on this type of study?

totally different situation here right?

although agonism of ER at certain other places can be beneficial to HDL but not sure by how much on gear users on multiple things (DHT based gear to AI here and there etc)

anybody else with lab results on torem and on gear?

of course off gear and torem (IME) gave great bloodwork tahts a no brainer.

Effect of toremifene in lowering total cholesterol, LDL, and triglycerides and raising HDL in prostate cancer patients on androgen deprivation therapy.


Sub-category:
Prostate Cancer

Category:
Genitourinary Cancer

Meeting:
2007 ASCO Annual Meeting

Session Type and Session Title:
General Poster Session, Genitourinary Cancer

Abstract No:
5124

Citation:
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 5124

Author(s):
M. Smith, F. Chu, J. Forrest, S. B. Malkowicz, D. Price, P. Sieber, K. G. Barnette, D. Rodriguez, M. S. Steiner

Abstract:

Introduction: Androgen deprivation therapy (ADT) is the standard treatment for men with advanced prostate cancer. ADT has been shown to detrimentally affect lipids (average 9% increase in total cholesterol and 26% increase in triglycerides) and is associated with increased risk of coronary heart disease and myocardial infarction. Toremifene, a selective estrogen receptor modulator (SERM), improves bone mineral density and lipid profiles in women. An ongoing phase III trial will assess the safety and efficacy of toremifene in treating multiple side effects of ADT including osteoporosis, hot flashes, gynecomastia and lipid profiles. Given the emerging recognition of increased cardiovascular risk during ADT, an interim analysis was conducted to assess the effects of toremifene on lipid profiles in the ongoing phase III study. Methods: 1,392 men = 50 years old with histologically documented prostate cancer and receiving ADT were randomized to toremifene (80 mg/day) or placebo. An interim analysis evaluated changes in lipids from baseline to month 12 in the first 197 subjects to complete one-year follow up. The outcomes measured in this interim analysis were total cholesterol, LDL cholesterol, triglycerides, total cholesterol/HDL ratio, and HDL cholesterol. Results: Compared to treatment with placebo, toremifene decreased total cholesterol (7.1%; p=0.001 for between group comparison), LDL cholesterol (9.0%; p=0.003), and triglycerides (20.1%; p=0.009) levels, and the total cholesterol/HDL ratio (11.7%; p<0.001). Toremifene also significantly increased HDL levels (5.4%; p=0.018) compared to placebo. The effects of toremifene were observed in both statin users and nonusers. Conclusions: Toremifene decreases total cholesterol, LDL cholesterol, and triglycerides and increases HDL cholesterol in men receiving ADT for advanced prostate cancer compared to placebo. Conclusions regarding the clinical significance of these observations will be based on the full cohort of patients at the conclusion of the trial.

 

[dragonfire101]

ya i couldn't find if the cohorts were maybe going to be NOT on androgen deprivation or a final study anywhere.

postmenopause and intentional andropause (ADT)

**broken link removed**

wonder how we gear users who are APT (androgen plenty therapy) lol would be like on this type of study?

totally different situation here right?

although agonism of ER at certain other places can be beneficial to HDL but not sure by how much on gear users on multiple things (DHT based gear to AI here and there etc)

anybody else with lab results on torem and on gear?

of course off gear and torem (IME) gave great bloodwork tahts a no brainer.